Skip to main content
    Johnson & Johnson logo

    Johnson & Johnson

    Health care

    TickerJNJISINUS4781601046

    Johnson & Johnson stock analysis: how the business works, what moves it and what to check

    How Johnson & Johnson makes money, what moves the stock, which figures to check and the risks to keep in view.

    Peakwise Research · · Updated · 4 min read

    Contents

    Johnson & Johnson is now a pure health care company: prescription drugs and medical devices, after it spun off its consumer brands as Kenvue in 2023. It is one of the few companies with a top credit rating, and a long-standing dividend holding.

    CompanyJohnson & Johnson
    TickerJNJ
    ListingNYSE
    SectorHealth Care
    ISINUS4781601046
    HeadquartersNew Brunswick, New Jersey, USA

    Johnson & Johnson at a glance

    • Focused on pharmaceuticals and medical technology.
    • Spun off the consumer business as Kenvue in 2023.
    • Long record of dividend increases.

    A short history

    Johnson & Johnson was founded in 1886 in New Brunswick, New Jersey. For decades it was known for consumer products such as Band-Aid and baby powder. It spun off its consumer health business as Kenvue in 2023 and now focuses on innovative medicine and medical technology.

    How Johnson & Johnson makes money

    Innovative Medicine sells prescription drugs in immunology, oncology, neuroscience and other areas. MedTech sells surgical, orthopaedic, cardiovascular and vision devices. Drugs make up the larger share of revenue.

    Competitive position

    J&J has one of the broadest pharma pipelines and a large medical devices business in surgery, orthopaedics and cardiovascular. Its strong balance sheet allows large acquisitions. Competitors include Pfizer, Merck & Co., AbbVie, Roche and in devices Medtronic, Stryker and Abbott.

    What moves Johnson & Johnson stock

    • Drug pipeline. New cancer and immunology drugs need to replace older blockbusters.
    • Loss of exclusivity. Stelara faces biosimilar competition, which hits sales.
    • MedTech growth. Cardiovascular and surgical devices add growth.
    • Litigation. Talc lawsuits have been a long-running overhang.

    Johnson & Johnson key figures, up to date

    JNJ

    The AI stock analysis computes these figures from current market data, with a short comment on each number and the method behind the fair value range.

    Free for 7 days. Not investment advice.

    The numbers worth checking

    Not every ratio matters equally for every company. For Johnson & Johnson, these are the figures that tell you the most. If a term is new, the guides on the P/E ratio and fair value explain the basics.

    • Pharma growth excluding Stelara. Shows how the rest of the portfolio is doing.
    • MedTech operational growth. Device momentum.
    • Free cash flow and dividend cover. Funds a dividend raised for decades.
    • Net debt. Acquisitions such as Shockwave and Intra-Cellular added debt.

    The best source for these figures is the latest annual or quarterly report on the Johnson & Johnson investor relations site. Our guide on how to read an earnings report shows where to find them.

    How to think about valuation

    J&J is valued on P/E and dividend yield as a defensive health care stock. Patent expiries and the pipeline determine growth expectations.

    Opportunities

    • New medicines. Oncology and immunology launches replace older products.
    • MedTech. Acquisitions add faster-growing device markets.
    • Balance sheet. Room for further acquisitions.

    Risks to keep in view

    • Biosimilar erosion. Patent expiries cut revenue fast.
    • Litigation. Large legal settlements.
    • Drug pricing reform. US price negotiations under the Inflation Reduction Act.

    A useful exercise is to write the bull case and the bear case for Johnson & Johnson in three sentences each. If you cannot fill the bear case, you have not looked hard enough. How to write an investment thesis walks through it.

    What to watch in the next report

    • Sales trends after Stelara patent expiry
    • Pipeline readouts
    • Litigation updates

    How to research Johnson & Johnson stock with Peakwise

    Open the AI stock analysis and look up JNJ. You get financials, news, analyst consensus, a fair value range (low, mid and high, with the method stated) and a list of risks and opportunities for Johnson & Johnson, plus a chat next to the report for follow-up questions.

    Johnson & Johnson is also one of the 50 large S&P 500 companies with a daily AI stock score for Johnson & Johnson. It ranks the stock from 0 to 100 against the rest of that list on momentum, trend, volatility, drawdown, quality and valuation, updated once per trading day from end of day prices. How the score is built.

    For anything the report leaves open, ask the investment chatbot. It runs a web search for each question and links the sources it used, so you can open them and check. A good first question:

    How fast is Stelara revenue falling after biosimilar launches, and which drugs are replacing it?

    To look at the chart itself, the AI chart analysis describes trend, support and resistance levels and patterns over one month, one year and the full history.

    This article describes the business and the questions worth asking. It contains no price targets and no forecasts, and it is not investment advice. Check current figures before you make a decision.

    Frequently asked questions

    No. Those consumer brands moved to Kenvue, which was separated from J&J in 2023.

    That depends on your goals, your time horizon and the price you pay, so no article can answer it for you. For Johnson & Johnson, the points that carry the most weight are drug pipeline, loss of exclusivity and, on the risk side, biosimilar erosion. Check them with current figures and decide for yourself. This is not investment advice.

    Biosimilar erosion. Patent expiries cut revenue fast. Litigation. Large legal settlements. Drug pricing reform. US price negotiations under the Inflation Reduction Act.

    On the Johnson & Johnson page in the Peakwise stock section. The score ranks Johnson & Johnson from 0 to 100 against 50 large S&P 500 companies and is updated once per trading day. It describes past data and is not a recommendation.

    Johnson & Johnson trades under the ticker JNJ. The ISIN is US4781601046. Listing: NYSE.

    Check Johnson & Johnson yourselfin one report

    The AI stock analysis puts financials, news, analyst consensus, a fair value range with its method, and risks and opportunities in one report.

    Free for 7 days. Not investment advice.